Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome

Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome

  • June 1, 2026

Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.

Leave A Comment

Fields (*) Mark are Required